Skip to content

Quick ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.3×+0.1×
Gilead Sciences logo
Gilead SciencesGILD
1.7×+0.5×
Precigen logo
PrecigenPGEN
4.1×+0.6×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
18×+2.3×
Sana Biotechnology logo
Sana BiotechnologySANA
1.3×-2.1×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
10.4×+8.7×

Other financials

Income statement

See full
Revenue-
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Calculated from Allogene Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's quick ratio?
Allogene Therapeutics (ALLO) reported quick ratio of 9.6× in Q1 2026.
How has Allogene Therapeutics's quick ratio changed year-over-year?
Allogene Therapeutics's quick ratio decreased by 0.7% year-over-year, from 9.7× to 9.6×.
What is the long-term trend for Allogene Therapeutics's quick ratio?
Over 5 years (2020 to 2025), Allogene Therapeutics's quick ratio has grown at a -2.4% compound annual growth rate (CAGR), from 9× to 7.9×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.